FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088049773> ?p ?o ?g. }

• W3088049773 endingPage "S510" @default.
• W3088049773 startingPage "S510" @default.
• W3088049773 abstract "Up to 30% of mCRPC men harbor DDR defects and may benefit from PARP inhibitors (PARPi) after abiraterone/enzalutamide and docetaxel failure. CBZ was recently shown to improve overall survival (OS) in this population, though benefit by DDR status is unknown. We assessed CBZ activity in men with mCRPC according to their DDR status. In this retrospective multicenter study, mCRPC patients (pts) who received CBZ were included if their DDR profile from tissue was available. Gene panels included at least BRCA1/2, ATM, CDK12 CHEK1/2, FANCA/FANCL, PALB2, RAD51. DDR positive (DDR+) pts could have had any deleterious germline or somatic DDR. For each DDR+ pts, DDR negative (DDR-) pts were randomly selected after matching for the same molecular test and institution, in a 1:1 ratio. PSA decline, radiological progression-free survival (rPFS) and OS were assessed. A total of 190 pts were included: 95 DDR+ and 95 DDR-. DDR+ pts were younger than DDR- (66 vs 69 years, p=0.026). The Gleason score was ≥8 in 66% and 55%, metastases (mts) were found at diagnosis in 51% and 41%, respectively. At CBZ start, pts had received a median of 2 prior life-prolonging agents, visceral mts in 24% and 26%, ECOG ≤1 in 78% and 80%, and a median PSA of 91 and 77 ng/ml, respectively. Among DDR+ pts, 40 (42%) had BRCA defects and 43 (45%) received a PARPi. A 50% PSA decline was achieved with CBZ in 29 (32%) and 33 (36%) in DDR+ and DDR- pts (p=0.64). Median rPFS was 5.33 months [95%CI 4.34-7.04] and 5.75 months [95%CI 4.67-7.27] (p=0.55), and median OS was 15.4 months [95%CI 12.16-26.6] and 11.5 months [95%CI 9.76-14.4] (p=0.036), respectively. An ECOG≥2 and visceral mts were independently associated with shorter OS. Outcomes of DDR+ pts are depicted in the Table, according to their sequence with PARPi.Table: 614MOCBZ no PARPi n=53CBZ before PARPi n=24CBZ after PARPi n=18Median prior lines223ECOG ≤136/53 (72%)22/24 (92%)12/18 (67%)Visceral mts13/53 (25%)5/24 (21%)4/18 (22%)50% PSA decline All pts BRCA+16/51 (31%) 10/39 (26%)10/24 (42%) 6/14 (43%)3/18 (17%) 0/10 (0%)Median rPFS (months) [95%CI]6.15 [3.68-8.38]5.97 [3.98-8.05]3.09 [0.98-6.57]Median OS (months) [95%CI]12.9 [10.2-20]42.5 [20.2-67.4]7.2 [5.29-13.41] Open table in a new tab CBZ is active in both DDR+ and DDR- mCRPC men. Activity may be lower in pts pre-treated with a PARPi, pending validation." @default.
• W3088049773 created "2020-10-01" @default.
• W3088049773 creator A5001456598 @default.
• W3088049773 creator A5007309998 @default.
• W3088049773 creator A5007779528 @default.
• W3088049773 creator A5008268754 @default.
• W3088049773 creator A5010328090 @default.
• W3088049773 creator A5021163421 @default.
• W3088049773 creator A5025502682 @default.
• W3088049773 creator A5030902321 @default.
• W3088049773 creator A5033332646 @default.
• W3088049773 creator A5039038711 @default.
• W3088049773 creator A5043416677 @default.
• W3088049773 creator A5050835714 @default.
• W3088049773 creator A5056852049 @default.
• W3088049773 creator A5058986790 @default.
• W3088049773 creator A5064376976 @default.
• W3088049773 creator A5066983589 @default.
• W3088049773 creator A5067036952 @default.
• W3088049773 creator A5067828312 @default.
• W3088049773 creator A5068223483 @default.
• W3088049773 creator A5088690292 @default.
• W3088049773 date "2020-09-01" @default.
• W3088049773 modified "2023-10-18" @default.
• W3088049773 title "614MO Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects" @default.
• W3088049773 doi "https://doi.org/10.1016/j.annonc.2020.08.873" @default.
• W3088049773 hasPublicationYear "2020" @default.
• W3088049773 type Work @default.
• W3088049773 sameAs 3088049773 @default.
• W3088049773 citedByCount "1" @default.
• W3088049773 countsByYear W30880497732022 @default.
• W3088049773 crossrefType "journal-article" @default.
• W3088049773 hasAuthorship W3088049773A5001456598 @default.
• W3088049773 hasAuthorship W3088049773A5007309998 @default.
• W3088049773 hasAuthorship W3088049773A5007779528 @default.
• W3088049773 hasAuthorship W3088049773A5008268754 @default.
• W3088049773 hasAuthorship W3088049773A5010328090 @default.
• W3088049773 hasAuthorship W3088049773A5021163421 @default.
• W3088049773 hasAuthorship W3088049773A5025502682 @default.
• W3088049773 hasAuthorship W3088049773A5030902321 @default.
• W3088049773 hasAuthorship W3088049773A5033332646 @default.
• W3088049773 hasAuthorship W3088049773A5039038711 @default.
• W3088049773 hasAuthorship W3088049773A5043416677 @default.
• W3088049773 hasAuthorship W3088049773A5050835714 @default.
• W3088049773 hasAuthorship W3088049773A5056852049 @default.
• W3088049773 hasAuthorship W3088049773A5058986790 @default.
• W3088049773 hasAuthorship W3088049773A5064376976 @default.
• W3088049773 hasAuthorship W3088049773A5066983589 @default.
• W3088049773 hasAuthorship W3088049773A5067036952 @default.
• W3088049773 hasAuthorship W3088049773A5067828312 @default.
• W3088049773 hasAuthorship W3088049773A5068223483 @default.
• W3088049773 hasAuthorship W3088049773A5088690292 @default.
• W3088049773 hasBestOaLocation W30880497731 @default.
• W3088049773 hasConcept C104317684 @default.
• W3088049773 hasConcept C121608353 @default.
• W3088049773 hasConcept C126322002 @default.
• W3088049773 hasConcept C126894567 @default.
• W3088049773 hasConcept C13514818 @default.
• W3088049773 hasConcept C141071460 @default.
• W3088049773 hasConcept C143998085 @default.
• W3088049773 hasConcept C185592680 @default.
• W3088049773 hasConcept C2776551883 @default.
• W3088049773 hasConcept C2778144015 @default.
• W3088049773 hasConcept C2780192828 @default.
• W3088049773 hasConcept C2781190966 @default.
• W3088049773 hasConcept C2908647359 @default.
• W3088049773 hasConcept C501734568 @default.
• W3088049773 hasConcept C55493867 @default.
• W3088049773 hasConcept C61367390 @default.
• W3088049773 hasConcept C71924100 @default.
• W3088049773 hasConcept C99454951 @default.
• W3088049773 hasConceptScore W3088049773C104317684 @default.
• W3088049773 hasConceptScore W3088049773C121608353 @default.
• W3088049773 hasConceptScore W3088049773C126322002 @default.
• W3088049773 hasConceptScore W3088049773C126894567 @default.
• W3088049773 hasConceptScore W3088049773C13514818 @default.
• W3088049773 hasConceptScore W3088049773C141071460 @default.
• W3088049773 hasConceptScore W3088049773C143998085 @default.
• W3088049773 hasConceptScore W3088049773C185592680 @default.
• W3088049773 hasConceptScore W3088049773C2776551883 @default.
• W3088049773 hasConceptScore W3088049773C2778144015 @default.
• W3088049773 hasConceptScore W3088049773C2780192828 @default.
• W3088049773 hasConceptScore W3088049773C2781190966 @default.
• W3088049773 hasConceptScore W3088049773C2908647359 @default.
• W3088049773 hasConceptScore W3088049773C501734568 @default.
• W3088049773 hasConceptScore W3088049773C55493867 @default.
• W3088049773 hasConceptScore W3088049773C61367390 @default.
• W3088049773 hasConceptScore W3088049773C71924100 @default.
• W3088049773 hasConceptScore W3088049773C99454951 @default.
• W3088049773 hasLocation W30880497731 @default.
• W3088049773 hasOpenAccess W3088049773 @default.
• W3088049773 hasPrimaryLocation W30880497731 @default.
• W3088049773 hasRelatedWork W122177069 @default.
• W3088049773 hasRelatedWork W1652439388 @default.
• W3088049773 hasRelatedWork W2021751111 @default.
• W3088049773 hasRelatedWork W2135620818 @default.
• W3088049773 hasRelatedWork W2568045406 @default.
• W3088049773 hasRelatedWork W2770702948 @default.

• next